Literature DB >> 24509332

Impaired renal function and bleeding in elderly treated with dabigatran.

Emmanuelle Berthelot1, Cecile Lavenu-Bombled, Lupe Orostegui-Giron, Céline Desconclois, Patrick Assayag.   

Abstract

Advantages of dabigatran, a thrombin inhibitor, for stroke prevention in patients with atrial fibrillation are numerous. Elderly patients with impaired renal function are at high risk of bleeding. Recommendations about the renal monitoring in elderly patients are not precise enough. The hemoclot direct thrombin inhibitor (HTI) assay measures accurately the dabigatran activity. Both could help managing serious bleeding events in selected populations. Four elderly patients recently treated with appropriate doses of dabigatran were hospitalized for major bleeding. Three patients were very elderly (> 80 years) and three had impaired renal function (clearance < 50 ml/min) before treatment initiation. Serious bleeding events occurred shortly after dabigatran initiation (< 2 months). In all cases, there was a documented dabigatran plasma overdose associated with a renal function impairment concomitant with the bleeding. Why should physicians be aware of this finding?: A close follow-up of the renal function in clinically fragile elderly patient, before and during the weeks following dabigatran initiation, could help to detect the risk of major bleeding event. The HTI dosage could help managing the treatment in case of severe bleeding event.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24509332     DOI: 10.1097/MBC.0000000000000077

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  1 in total

1.  Idarucizumab to revert the anticoagulant effect of dabigatran in traumatic acute subdural haematoma: a case report of first use in Latin America.

Authors:  Raúl Izaguirre Ávila; José Eduardo Bahena López; Evelyn Cortina de la Rosa; Miguel Ángel Hernández Márquez
Journal:  Eur Heart J Case Rep       Date:  2019-06-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.